Jui-Lin Chen, CEO of MiCareo, provides insights into the development of MiSelect, Micareo’s pioneering platform for the analysis of Circulating Tumor Cells (CTC) and other rare cells, which proudly stands as the best product available to physicians for cancer prognosis as well as the perfect companion diagnostic for drug development and efficacy evaluation. He also documents MiCareo’s overarching focus on delivering pioneering solutions targeting unmet needs in rare cell processing for personalized medicine, immunotherapies, clinical diagnostics, and biomarker discovery.
Could you walk us through the main milestones of the company and explain how you became MiCareo’s CEO in 2011?
"We truly held a groundbreaking technology in an emerging field where only “me-too” and “me-better” products were available in the international market."
